Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 Aug 17;83(6):719–724. doi: 10.1054/bjoc.2000.1331

Prevalence of BRCA1 in a hospital-based population of Dutch breast cancer patients

H Papelard 1,2, G H de Bock 1, R van Eijk 3, T P M Vliet Vlieland 1, C J Cornelisse 3, P Devilee 3,4, R A E M Tollenaar 2
PMCID: PMC2363536  PMID: 10952774

Abstract

The prevalence of disease-related BRCA1 mutations was investigated in 642 Dutch breast cancer patients not selected for family history or age at diagnosis. They were tested for germline mutations in the BRCA1 gene using an assay which detects small deletions and insertions (DSDI), as well as the two major genomic founder deletions present in the Dutch population. Data on family history and bilateral breast cancer were obtained retrospectively. Ten protein truncating mutations were detected and one in-frame deletion with an unknown relation to disease risk. Four patients carried the Dutch founder deletion of exon 22. Based on these results the estimated prevalence of breast cancer in the general population in the Netherlands attributable to BRCA1 mutations is 2.1%. Under 40 years-of-age and under 50 years-of-age this prevalence is 9.5% and 6.4%, respectively. All mutation carriers were under 50 years-of-age at diagnosis of the first breast cancer, and five did not have any relative with breast cancer. The proportions of bilateral breast cancer in the mutation carriers and non-carriers did not differ from each other. These data indicate that in the general Dutch breast cancer population the great majority of BRCA1 mutations will be found in women diagnosed under 50 years-of-age. © 2000 Cancer Research Campaign

Keywords: BRCA1 prevalence, general breast cancer population, Dutch founder mutations

Full Text

The Full Text of this article is available as a PDF (70.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abeliovich D., Kaduri L., Lerer I., Weinberg N., Amir G., Sagi M., Zlotogora J., Heching N., Peretz T. The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. Am J Hum Genet. 1997 Mar;60(3):505–514. [PMC free article] [PubMed] [Google Scholar]
  2. Couch F. J., DeShano M. L., Blackwood M. A., Calzone K., Stopfer J., Campeau L., Ganguly A., Rebbeck T., Weber B. L. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med. 1997 May 15;336(20):1409–1415. doi: 10.1056/NEJM199705153362002. [DOI] [PubMed] [Google Scholar]
  3. Devilee P. BRCA1 and BRCA2 testing: weighing the demand against the benefits. Am J Hum Genet. 1999 Apr;64(4):943–948. doi: 10.1086/302350. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Easton D. F., Ford D., Bishop D. T. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet. 1995 Jan;56(1):265–271. [PMC free article] [PubMed] [Google Scholar]
  5. FitzGerald M. G., MacDonald D. J., Krainer M., Hoover I., O'Neil E., Unsal H., Silva-Arrieto S., Finkelstein D. M., Beer-Romero P., Englert C. Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer. N Engl J Med. 1996 Jan 18;334(3):143–149. doi: 10.1056/NEJM199601183340302. [DOI] [PubMed] [Google Scholar]
  6. Fodor F. H., Weston A., Bleiweiss I. J., McCurdy L. D., Walsh M. M., Tartter P. I., Brower S. T., Eng C. M. Frequency and carrier risk associated with common BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer patients. Am J Hum Genet. 1998 Jul;63(1):45–51. doi: 10.1086/301903. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Ford D., Easton D. F., Peto J. Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet. 1995 Dec;57(6):1457–1462. [PMC free article] [PubMed] [Google Scholar]
  8. Hartge P., Struewing J. P., Wacholder S., Brody L. C., Tucker M. A. The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews. Am J Hum Genet. 1999 Apr;64(4):963–970. doi: 10.1086/302320. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Hogervorst F. B., Cornelis R. S., Bout M., van Vliet M., Oosterwijk J. C., Olmer R., Bakker B., Klijn J. G., Vasen H. F., Meijers-Heijboer H. Rapid detection of BRCA1 mutations by the protein truncation test. Nat Genet. 1995 Jun;10(2):208–212. doi: 10.1038/ng0695-208. [DOI] [PubMed] [Google Scholar]
  10. Langston A. A., Malone K. E., Thompson J. D., Daling J. R., Ostrander E. A. BRCA1 mutations in a population-based sample of young women with breast cancer. N Engl J Med. 1996 Jan 18;334(3):137–142. doi: 10.1056/NEJM199601183340301. [DOI] [PubMed] [Google Scholar]
  11. Ligtenberg M. J., Hogervorst F. B., Willems H. W., Arts P. J., Brink G., Hageman S., Bosgoed E. A., Van der Looij E., Rookus M. A., Devilee P. Characteristics of small breast and/or ovarian cancer families with germline mutations in BRCA1 and BRCA2. Br J Cancer. 1999 Mar;79(9-10):1475–1478. doi: 10.1038/sj.bjc.6690235. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Malone K. E., Daling J. R., Thompson J. D., O'Brien C. A., Francisco L. V., Ostrander E. A. BRCA1 mutations and breast cancer in the general population: analyses in women before age 35 years and in women before age 45 years with first-degree family history. JAMA. 1998 Mar 25;279(12):922–929. doi: 10.1001/jama.279.12.922. [DOI] [PubMed] [Google Scholar]
  13. Miki Y., Swensen J., Shattuck-Eidens D., Futreal P. A., Harshman K., Tavtigian S., Liu Q., Cochran C., Bennett L. M., Ding W. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994 Oct 7;266(5182):66–71. doi: 10.1126/science.7545954. [DOI] [PubMed] [Google Scholar]
  14. Miller S. A., Dykes D. D., Polesky H. F. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988 Feb 11;16(3):1215–1215. doi: 10.1093/nar/16.3.1215. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Newman B., Mu H., Butler L. M., Millikan R. C., Moorman P. G., King M. C. Frequency of breast cancer attributable to BRCA1 in a population-based series of American women. JAMA. 1998 Mar 25;279(12):915–921. doi: 10.1001/jama.279.12.915. [DOI] [PubMed] [Google Scholar]
  16. Peelen T., van Vliet M., Petrij-Bosch A., Mieremet R., Szabo C., van den Ouweland A. M., Hogervorst F., Brohet R., Ligtenberg M. J., Teugels E. A high proportion of novel mutations in BRCA1 with strong founder effects among Dutch and Belgian hereditary breast and ovarian cancer families. Am J Hum Genet. 1997 May;60(5):1041–1049. [PMC free article] [PubMed] [Google Scholar]
  17. Petrij-Bosch A., Peelen T., van Vliet M., van Eijk R., Olmer R., Drüsedau M., Hogervorst F. B., Hageman S., Arts P. J., Ligtenberg M. J. BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients. Nat Genet. 1997 Nov;17(3):341–345. doi: 10.1038/ng1197-341. [DOI] [PubMed] [Google Scholar]
  18. Shattuck-Eidens D., Oliphant A., McClure M., McBride C., Gupte J., Rubano T., Pruss D., Tavtigian S. V., Teng D. H., Adey N. BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing. JAMA. 1997 Oct 15;278(15):1242–1250. [PubMed] [Google Scholar]
  19. Shuber A. P., Grondin V. J., Klinger K. W. A simplified procedure for developing multiplex PCRs. Genome Res. 1995 Dec;5(5):488–493. doi: 10.1101/gr.5.5.488. [DOI] [PubMed] [Google Scholar]
  20. Southey M. C., Tesoriero A. A., Andersen C. R., Jennings K. M., Brown S. M., Dite G. S., Jenkins M. A., Osborne R. H., Maskiell J. A., Porter L. BRCA1 mutations and other sequence variants in a population-based sample of Australian women with breast cancer. Br J Cancer. 1999 Jan;79(1):34–39. doi: 10.1038/sj.bjc.6690008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Struewing J. P., Hartge P., Wacholder S., Baker S. M., Berlin M., McAdams M., Timmerman M. M., Brody L. C., Tucker M. A. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med. 1997 May 15;336(20):1401–1408. doi: 10.1056/NEJM199705153362001. [DOI] [PubMed] [Google Scholar]
  22. Tonin P., Weber B., Offit K., Couch F., Rebbeck T. R., Neuhausen S., Godwin A. K., Daly M., Wagner-Costalos J., Berman D. Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families. Nat Med. 1996 Nov;2(11):1179–1183. doi: 10.1038/nm1196-1179. [DOI] [PubMed] [Google Scholar]
  23. Wooster R., Bignell G., Lancaster J., Swift S., Seal S., Mangion J., Collins N., Gregory S., Gumbs C., Micklem G. Identification of the breast cancer susceptibility gene BRCA2. Nature. 1995 Dec 21;378(6559):789–792. doi: 10.1038/378789a0. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES